Syntec Optics (OPTX) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
12 Feb, 2026Executive summary
Q3 2025 net sales were $7.0 million, up 6% sequentially but down 11% year-over-year, with a net loss of $1.4 million, or $0.04 per share, compared to near breakeven in Q3 2024.
Gross profit margin declined to 12% in Q3 2025 from 23% in Q3 2024, mainly due to higher labor, overhead, and material costs.
Adjusted EBITDA for Q3 2025 was nearly zero, down from $1.1 million in Q3 2024, impacted by lower gross profit and increased expenses.
Operational improvements and investments in labor and manufacturing enhanced delivery and quality, though temporarily reduced gross margin.
General and administrative expenses rose 20% in Q3 2025, driven by higher management and audit fees.
Financial highlights
Q3 2025 net sales: $6.95–$7.0 million, up 6% sequentially but down from $7.87 million in Q3 2024; nine-month sales: $20.58 million (down from $21.13 million).
Gross profit for Q3 2025: $0.85–$0.9 million, down from $1.83 million in Q3 2024 and $1.56 million in Q2 2025.
Adjusted EBITDA for Q3 2025 was $(12.6)K to $(10)K, compared to $1.1 million in Q3 2024; year-to-date adjusted EBITDA was $2.07 million.
Net loss for Q3 2025 was $1.4–$1.43 million, or $0.04 per share, compared to $0.01 per share loss in Q2 and Q3 2024.
Cash at quarter end was $0.58–$0.6 million, with $0.7 million available under the credit facility.
Outlook and guidance
Q4 2025 revenue expected in the range of $7.3–$8.0 million, indicating continued sequential growth, with margin improvements anticipated from yield, throughput, and cost-down initiatives.
Management expects to maintain compliance with amended credit covenants and believes liquidity is sufficient for the remainder of 2025.
Confidence in long-term growth, supported by strong customer base, expanding product portfolio, and industry tailwinds.
Latest events from Syntec Optics
- Strong H1 2025 profit growth and margin expansion driven by defense, biomedical, and communications.OPTX
Q2 202513 Feb 2026 - Gross margin rose to 29% in H1 2025 as sales and adjusted EBITDA improved year-over-year.OPTX
Q4 202413 Feb 2026 - Q1 2025 net income turned positive on 13% sales growth and improved margins.OPTX
Q1 202513 Feb 2026 - Q2 sales up 12% sequentially, product growth strong, and Q3 outlook robust.OPTX
Q2 20242 Feb 2026 - Q3 sales up 19% year-over-year, but higher costs led to a net loss; Q4 outlook is positive.OPTX
Q3 202413 Jan 2026 - Virtual meeting to vote on directors, auditor, RSUs, and governance amendments; board recommends approval.OPTX
Proxy Filing8 Dec 2025 - Shareholders will vote on director elections, auditor ratification, and RSU grants at the virtual annual meeting.OPTX
Proxy Filing2 Dec 2025 - Shareholders will vote on directors, auditor ratification, RSU grants, and governance amendments.OPTX
Proxy Filing29 Nov 2025